Kardigan, Inc. (KARD) shareholders
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin Anthony Kelly Joint filing with Hrtg Gpe, LLC ("hrtg") (18.20%), Keith Bryon Johnson (18.20%) and 1 more | 16,917,034 | 18.20% | 13G (passive) | Jun 22, 2026 |
| Paul Berns Joint filing with ARCH Venture Fund XIII, L.P. (16.20%), ARCH Venture Partners XIII, L.P. (16.20%) and 5 more | 15,095,518 | 16.20% | 13D (active) | Jun 22, 2026 |
| Gianakakos Anastasios | 10,470,294 | 11.10% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (10.30%) | 9,221,774 | 10.30% | 13G (passive) amendment | Jul 31, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (8.90%), Perceptive Capital Solutions Holdings LP (6.20%) | 8,254,144 | 8.90% | 13D (active) | Jun 18, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (8.80%), Perceptive Capital Solutions Holdings LP (6.20%) | 8,254,144 | 8.80% | 13D (active) amendment | Sep 29, 2026 |
| Edelberg Jay | 4,878,105 | 5.20% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KARD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Schf (Gpe), LLC | 16,917,034 | 18.09% | $403.47M | New | 16.26% |
| FMR LLC | 8,909,066 | 9.53% | $212.48M | New | 0.01% |
| Perceptive Advisors LLC | 8,200,662 | 8.77% | $195.59M | New | 2.94% |
| T. Rowe Price Investment Management, Inc. | 4,207,130 | 4.50% | $100.34M | New | 0.07% |
| Capital Research Global Investors | 3,598,942 | 3.85% | $85.83M | New | 0.01% |
| JPMorgan Chase & Co | 1,790,734 | 1.92% | $46.38M | New | 0.00% |
| Alliancebernstein L.P. | 1,534,837 | 1.64% | $36.61M | New | 0.01% |
| Liberty Mutual Group Asset Management Inc. | 1,196,411 | 1.28% | $28.53M | New | 2.49% |
| Jennison Associates LLC | 903,575 | 0.97% | $21.55M | New | 0.01% |
| Paradigm Biocapital Advisors LP | 900,000 | 0.96% | $21.47M | New | 0.40% |
| Jupiter Topco LLC | 749,703 | 0.80% | $17.72M | New | 0.01% |
| Price T Rowe Associates Inc /Md/ | 658,787 | 0.70% | $15.71M | New | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 650,000 | 0.70% | $15.50M | New | 0.00% |
| Goldman Sachs Group Inc | 644,969 | 0.69% | $15.38M | New | 0.00% |
| Deep Track Capital, LP | 600,000 | 0.64% | $14.31M | New | 0.21% |
| Woodline Partners LP | 413,980 | 0.44% | $9.87M | New | 0.03% |
| Franklin Resources Inc | 400,021 | 0.43% | $9.54M | New | 0.00% |
| Suvretta Capital Management, LLC | 400,000 | 0.43% | $9.54M | New | 0.17% |
| Bank of New York Mellon Corp | 377,758 | 0.40% | $9.01M | New | 0.00% |
| Catalio Capital Management, LP | 312,500 | 0.33% | $7.45M | New | 1.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 69 | 57M | 61.2% | 69 / 0 | 0 / 0 | 57M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KARD | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,503,842 | 3.75% | $83.57M | 0.09% | Jun 30, 2026 |
| Fidelity Contrafund | 1,090,645 | 1.17% | $26.01M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 823,598 | 0.88% | $19.64M | 0.75% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 741,883 | 0.79% | $17.69M | 0.56% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 737,233 | 0.79% | $17.58M | 0.19% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 633,307 | 0.68% | $15.10M | 0.14% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 596,411 | 0.64% | $14.22M | 0.80% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 445,253 | 0.48% | $10.62M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 398,570 | 0.43% | $9.51M | 0.19% | Jun 30, 2026 |
| Fidelity Blue Chip Growth Fund | 352,100 | 0.38% | $7.33M | 0.01% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 300,000 | 0.32% | $7.16M | 0.40% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 265,242 | 0.28% | $6.33M | 0.37% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 227,493 | 0.24% | $5.43M | 0.01% | Jun 30, 2026 |
| SmallCap Growth Fund I | 225,647 | 0.24% | $4.70M | 0.19% | Jul 31, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 182,297 | 0.19% | $4.35M | 0.50% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anastasios Gianakakos | President & CEO, Director | 9,806,633 | 10.49% | Jun 22, 2026 |
| John B. Moriarty | Chief Legal Officer | 47,784 | 0.05% | Jun 22, 2026 |
| Jay Edelberg | Chief Medical Officer | 4,595,383 | 4.91% | Jun 22, 2026 |
| Andy Pasternak | Chief Strategy Officer | 79,640 | 0.09% | Jun 22, 2026 |
| Brianne Jahn | Chief Financial Officer | 79,640 | 0.09% | Jun 22, 2026 |
| Kristin Marie K. Reinke | Director | – | – | Oct 1, 2026 |
| Advisors Llc Perceptive | Director | – | – | Jul 13, 2026 |
| Capital Solutions Holdings LP Perceptive | Director | – | – | Jul 13, 2026 |
| Joseph Edelman | Director | 20,706 | 0.02% | Jul 13, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | – | – | Jul 13, 2026 |
| Kristina Burow | Director, 10% owner | – | – | Jun 24, 2026 |
| Paul L. Berns | Director, 10% owner | 15,062,741 | 16.11% | Jun 24, 2026 |
| Steven Gillis | Director, 10% owner | – | – | Jun 24, 2026 |
| ARCH Venture Partners XIII, LLC | Director, 10% owner | – | – | Jun 24, 2026 |
| ARCH Venture Fund XIII, L.P. | Director, 10% owner | – | – | Jun 24, 2026 |
| ARCH Venture Partners XIII, L.P. | Director, 10% owner | – | – | Jun 24, 2026 |
| Keith Crandell | Director, 10% owner | – | – | Jun 24, 2026 |
| Robert Nelsen | Director, 10% owner | 15,042,035 | 16.09% | Jun 24, 2026 |
| David P. Meeker | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Kimberly J. Popovits | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Douglas E. Giordano | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Timothy P. Walbert | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Keith Bryon Johnson | 10% owner | 13,792,034 | 14.75% | Jun 24, 2026 |
| Kevin Anthony Kelly | 10% owner | – | – | Jun 24, 2026 |
| Schf Cif 2024, L.P. | 10% owner | – | – | Jun 24, 2026 |
| Hrtg Pv, L.P. | 10% owner | 16,917,034 | 18.09% | Jun 24, 2026 |
| Hrtg Gpe, Llc | 10% owner | – | – | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Nelsen Director, 10% owner | Jun 22, 2026 | Buy | +1,250,000 | $16.00 | $20.00M | 15,042,035 |
| Paul L. Berns Director, 10% owner | Jun 22, 2026 | Buy | +1,250,000 | $16.00 | $20.00M | 15,042,035 |
| Hrtg Pv, L.P. 10% owner | Jun 22, 2026 | Buy | +3,125,000 | $16.00 | $50.00M | 14,866,868 |
| Joseph Edelman Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Douglas E. Giordano Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Andy Pasternak Chief Strategy Officer | Jun 17, 2026 | Award | +79,640 | – | – | 79,640 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +2,348,373 | – | – | 11,741,868 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +3,242,993 | – | – | 9,393,495 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +6,150,502 | – | – | 6,150,502 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +2,050,166 | – | – | 2,050,166 |
| Brianne Jahn Chief Financial Officer | Jun 17, 2026 | Award | +79,640 | – | – | 79,640 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +41,001 | – | – | 2,422,520 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +28,702 | – | – | 5,665,090 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +498,692 | – | – | 498,692 |
| John B. Moriarty Chief Legal Officer | Jun 17, 2026 | Award | +47,784 | – | – | 47,784 |
| Jay Edelberg Chief Medical Officer | Jun 17, 2026 | Conversion | +97,587 | – | – | 135,543 |
| Jay Edelberg Chief Medical Officer | Jun 17, 2026 | Award | +47,784 | – | – | 183,327 |
| Kimberly J. Popovits Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Paul L. Berns Director, 10% owner | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Paul L. Berns Director, 10% owner | Jun 17, 2026 | Conversion | +13,792,035 | – | – | 13,792,035 |
| Robert Nelsen 10% owner | Jun 17, 2026 | Conversion | +13,792,035 | – | – | 13,792,035 |
| Timothy P. Walbert Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| David P. Meeker Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 5 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kardigan's stock actually held short. Settlement fails (shares not delivered on time) peaked at 89,530 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?